Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously Vaccinated as Adolescents With Either MenACWY Conjugate Vaccine or Menomune®.

NCT01018732 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01018732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01018732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously Vaccinated as Adolescents With Either MenACWY Conjugate Vaccine or Menomune®.
Lead sponsor
Novartis Vaccines
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2010
Completion date
July 31, 2010
Enrollment
155 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease, meningococcal meningitis